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Role of potassium channels in the antinociception induced by
agonists of a2-adrenoceptors
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1 The eect of the administration of pertussis toxin (PTX) as well as modulators of dierent
subtypes of K+ channels on the antinociception induced by clonidine and guanabenz was evaluated
in the mouse hot plate test.
2 Pretreatment with pertussis toxin (0.25 mg per mouse i.c.v.) 7 days before the hot-plate test,
prevented the antinociception induced by both clonidine (0.08 – 0.2 mg kg71, s.c.) and guanabenz
(0.1 – 0.5 mg kg71, s.c.).
3 The administration of the KATP channel openers minoxidil (10 mg per mouse, i.c.v.), pinacidil
(25 mg per mouse, i.c.v.) and diazoxide (100 mg kg71, p.o.) potentiated the antinociception produced
by clonidine and guanabenz whereas the KATP channel blocker gliquidone (6 mg per mouse, i.c.v.)
prevented the a2 adrenoceptor agonist-induced analgesia.
4 Pretreatment with an antisense oligonucleotide (aODN) to mKv1.1, a voltage-gated K+ channel,
at the dose of 2.0 nmol per single i.c.v. injection, prevented the antinociception induced by both
clonidine and guanabenz in comparison with degenerate oligonucleotide (dODN)-treated mice.
5 The administration of the Ca2+-gated K+ channel blocker apamin (0.5 – 2.0 ng per mouse, i.c.v.)
never modified clonidine and guanabenz analgesia.
6 At the highest eective doses, none of the drugs used modified animals’ gross behaviour nor
impaired motor coordination, as revealed by the rota-rod test.
7 The present data demonstrate that both KATP and mKv1.1 K
+ channels represent an important
step in the transduction mechanism underlying central antinociception induced by activation of a2
adrenoceptors.
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Introduction
Agonists of a2-adrenoceptors produce a wide variety of
eects. These include an antihypertensive action, alleviation
of opiate-withdrawal syndrome, antinociception and sedation
(Fielding & Lal, 1981; McDonald et al., 1997). Clonidine, an
agonist of a2-adrenoceptors, is extremely potent as an
antinociceptive agent showing equal or greater potency than
morphine in rodents (Fielding et al., 1978). Clonidine has
been shown to exhibit antinociceptive activity against a wide
variety of noxious stimuli such as chemical irritants, heat,
pressure and electrical stimuli (Fielding & Lal, 1981; Skingle
et al., 1982).
Clonidine and other agonists of a2-adrenoceptors hyperpo-
larize neuronal membranes by opening K+ channels (Morita &
North, 1981; Andrade & Aghajanian, 1985; Tatsumi et al.,
1990). It has also been reported that clonidine antinociception
is antagonized by blockers of ATP-dependent K+ channels
(Ocana & Bayens, 1993; Raa & Martinez, 1995). A possible
relationship between the eects on KATP conductance and
enhancement of the pain threshold produced by activation of
a2-adrenoceptors has, therefore, been postulated.
Since several kinds of K+ channels with dierent
electrophysiological characteristics and pharmacological sensi-
tivities have been described in neurones (Halliwell, 1990;
Aronson, 1992), in the present work we thought it worthwhile
to employ dierent K+ channel modulators to elucidate better
the role of K+ channels in the antinociception induced by a2-
adrenoceptor agonists. Apamin has been reported to block
specifically currents through the Ca2+-activated K+ channels
(Cook, 1988). Sulphonylureas such as gliquidone block KATP
channels in neurones whereas minoxidil, pinacidil and
diazoxide open the same type (KATP) of K
+ channel (Edwards
& Weston, 1993). So far, the blockers of neuronal voltage-
dependent K+ channels are not selective for any channels in
particular (Cook & Quast, 1990; Halliwell, 1990). An antisense
oligonucleotide (aODN) was, therefore, used to selectively
block the expression of the gene coding for mKv1.1, a voltage-
gated K+ channel (Wang et al., 1994).
To this purpose we have evaluated the eects produced by
the K+ channel blockers apamin and gliquidone, the K+
channel openers minoxidil, pinacidil and diazoxide, as well as
an aODN to mKv1.1 in the antinociception induced by a2-
adrenoceptor agonists in the mouse hot-plate test.
Clonidine analgesia has been reported to be prevented by
intracerebroventricular administration of pertussis toxin
(PTX) (Sanchez-Blasquez & Garzon, 1991). We, therefore,
investigated whether also guanabenz analgesia was sensitive to
pertussis toxin pretreatment taking into account that a2-
adrenoceptors are coupled to pertussis toxin-sensitive G-
proteins which in turn can regulate ionic conductance
(Aghajanian & Wang, 1986).*Author for correspondence; E-mail: ghelard@server1.pharm.unifi.it
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Methods
Animals
Male Swiss albino mice (23 – 30 g) from the Morini (San
Polo d’Enza, Italy) breeding farm were used. Fifteen mice
were housed per cage. The cages were placed in the
experimental room 24 h before the test for acclimatization.
The animals were fed a standard laboratory diet and tap
water ad libitum and kept at 23+18C with a 12 h light/dark
cycle, light on at 07.00 h. Animals were used a single time
with the exception of the aODN experiments. Experiments
were conducted 72 h and 7 days after the end of the aODN
treatment. Each animal was, therefore, used twice (at 72 h
and at day 7). All experiments were carried out according to
the guidelines of the European Community Council for
experimental animal care.
Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was performed
under ether anaesthesia, according to the method described by
Haley & McCormick (1957). Briefly, during anaesthesia, mice
were grasped firmly by the loose skin behind the head. A
0.4 mm external diameter hypodermic needle attached to a
10 ml syringe was inserted perpendicularly through the skull
and no more than 2 mm into the brain of the mouse, where
5 ml were then administered. The injection site was 1 mm to the
right or left from the midpoint on a line drawn through to the
anterior base of the ears. Injections were performed into the
right or left ventricle randomly. To ascertain that the drugs
were administered exactly into the cerebral ventricle, some
mice (20%) were injected with 5 ml of diluted 1 : 10 India ink
and their brains examined macroscopically after sectioning.
The accuracy of the injection technique was evaluated and the
percentage of correct injections was 95.
Hot-plate test
The method adopted was described by O’Callaghan &
Holtzman (1975). Mice were placed inside a stainless steel
container, which was set thermostatically at 52.5+0.18C in a
precision water-bath from KW Mechanical Workshop, Siena,
Italy. Reaction times (s), were measured with a stopwatch
before and 15, 30, 45 and 60 min after clonidine treatment or
15, 30, 45, 60, 75, 90, 120 and 180 min after guanabenz
administration. The endpoint used was the licking of the fore
or hind paws. Those mice scoring less than 12 and more than
18 s in the pretest were rejected (30%). An arbitrary cut-o
time of 45 s was adopted.
The licking latency values reported in all figures were
evaluated in relation to the maximum analgesic eect of
clonidine and guanabenz which were respectively 30 and
75 min after administration.
Rota-rod test
The apparatus consisted of a base platform and a rotating rod
of 3 cm diameter with a non-slippery surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm in
length, was divided into five equal sections by six disks. Thus,
up to five mice were tested simultaneously on the apparatus,
with a rod-rotating speed of 16 r.p.m. The integrity of motor
coordination was assessed on the basis of the number of falls
from the rod in 30 s according to Vaught et al. (1985). Those
mice scoring less than 3 and more than 6 falls in the pretest
were rejected (20%). The performance time was measured
before and 15, 30, 45 and 60 min after treatment with the
exception of animals treated with guanabenz which were tested
up to 120 min after injection.
Antisense oligonucleotides
The 24mer phosphodiester oligonucleotides were capped by a
terminal phosphorothioate double substitution and purified by
chromatography (Genosys, The Woodlands, U.S.A.). The
antisense ODN (5’-CGA CAT CAC CGT CAT GAT
GAA AGC-3’) was designed to target the 5’ portion of the
murine Kv1.1 (mKv1.1) mRNA, residues 575 – 598 of the
published cDNA sequence (Chandy et al., 1990). A fully
degenerate 24mer ODN (dODN) was used as control.
Mice were randomly assigned to antisense oligodeoxy-
ribonucleotide (mKv1.1 aODN), degenerate oligodeoxyribo-
nucleotide (mKv1.1 dODN) or vector groups. 400 mM
ODNs were preincubated at 378C for 30 min with 13 mM
DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylam-
moniummethyl sulphate), used as vector. Each group received
a single intracerebroventricular (i.c.v.) injection on days 1, 4
and 7. The experimental conditions for the antisense studies
(time, dose and decreases in mRNA levels) have been chosen
on the basis of previous studies (Galeotti et al., 1997).
Drugs
The following drugs were used: clonidine hydrochloride,
guanabenz acetate, minoxidil, pinacidil, apamin, diazoxide,
pertussis toxin (RBI); gliquidone (Boehringer Ingelheim).
Drugs were dissolved in isotonic (NaCl 0.9%) saline
solution, with the exception of pinacidil, that was dissolved
in a water and dimethyl sulphoxide (DMSO) (3 : 1) vehicle, and
diazoxide, which was dispersed in a 1% solution of sodium
carboxymethyl cellulose, immediately before use. Drug
concentrations were prepared in such a way that the necessary
dose could be administered in a volume of 5 ml per mouse by
i.c.v. injection and 10 ml kg71 by esophageal (p.o.) and
subcutaneous (s.c.) injection.
Apamin, gliquidone, minoxidil and pinacidil were injected
i.c.v. whereas diazoxide was administered p.o.; all drugs were
injected 15 min before the test. The drug administration
schedule was chosen on the basis of preliminary experiments
in which the time-course and the dose-response curves in the
hot-plate test for every compound were determined.
Concerning pertussis toxin treatment, mice were randomly
assigned to a vehicle (water solution containing 0.01 M sodium
phosphate buer, pH=7.0, with 0.05 M sodium chloride) or a
pertussis toxin group (0.25 mg per mouse) which received a
single i.c.v. injection on day 0. The hot-plate test was
performed 7 days after pretreatment.
Following the pretreatment schedule with saline, vehicle,
aODN or dODN mentioned in the above section, the
antinociceptive eect of clonidine and guanabenz was tested
72 h and 7 days after the last i.c.v. injection.
Statistical analysis
All experimental results are given as the mean+s.e.mean.
Analysis of variance (ANOVA), followed by Fisher’s
Protected Least Significant Dierence (PLSD) procedure for
post hoc comparison, and overall ANOVA were used to verify
significance between two means. Data were analysed with the
StatView software for the Macintosh (1992). P values of less
than 0.05 were considered significant.
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Results
Eect of pertussis toxin on clonidine and guanabenz
antinociception
Both clonidine (0.08 – 0.20 mg kg71, s.c.) and guanabenz
(0.05 – 0.50 mg kg71, s.c.) produced a dose-dependent anti-
nociception in the mouse hot-plate test (Figure 1). Pertussis
toxin, administered at the dose of 0.25 mg per mouse i.c.v. 7
days prior to the test, led to a prevention of the antinociceptive
eect of clonidine (Figure 1a) and guanabenz (Figure 1b).
Eect of KATP channel modulators on clonidine and
guanabenz antinociception
The eect produced by the KATP channel openers diazoxide
(100 mg kg71, p.o.), minoxidil (10 mg per mouse, i.c.v.) and
pinacidil (25 mg per mouse, i.c.v.) on the antinociception
induced by clonidine (0.125 mg kg71, s.c.) and guanabenz
(0.30 mg kg71, s.c.) was investigated in the mouse hot-plate
test (Figure 2). All K+ channel openers potentiated the
antinociceptive activity of both a2-adrenoceptor agonists
investigated (Figure 2). Furthermore, pinacidil (25 mg per
mouse i.c.v.), taken as an example, exerted its potentiating
eect at various doses of clonidine (0.05 – 0.20 mg kg71, s.c.;
Figure 3a) and guanabenz (0.05 – 0.30 mg kg71, s.c.; Figure
3b), shifting to the left their dose-response curves.
Figure 1 Eect of pertussis toxin (PTX) pretreatment on clonidine-
and guanabenz-induced antinociception in the mouse hot-plate test.
(a) Prevention by PTX (0.25 mg per mouse, i.c.v.) of clonidine (0.05 –
0.20 mg kg71, s.c.) antinociception. The test was performed 7 days
after a single i.c.v. injection of vehicle or PTX. Vertical lines
represent s.e.mean; between 11 and 16 mice were tested. *P50.05,
**P50.01 in comparison with vehicle-clonidine treated mice. (b)
Prevention by PTX (0.25 mg per mouse, i.c.v.) of guanabenz (0.02 –
0.50 mg kg71, s.c.) antinociception. The test was performed 7 days
after a single i.c.v. injection of vehicle or PTX. Vertical lines
represent s.e.mean; between 12 and 19 mice were tested. *P50.05,
**P50.01 in comparison with vehicle-guanabenz treated mice.
Figure 2 Enhancement of clonidine (0.125 mg kg71, s.c.) and
guanabenz (0.30 mg kg71, s.c.) antinociception by the KATP openers
diazoxide (100 mg kg71, p.o.), minoxidil (10 mg per mouse i.c.v.) and
pinacidil (25 mg per mouse, i.c.v.) in the mouse hot plate test. Vertical
lines represent s.e.mean; between 12 and 16 mice were tested.
*P50.05 in comparison with corresponding analgesic drug-treated
mice.
Figure 3 Eect of pinacidil on dierent doses of clonidine and
guanabenz in the mouse hot-plate test. (a) Enhancement by pinacidil
(25 mg per mouse, i.c.v.) of clonidine (0.05 – 0.20 mg kg71, s.c.)
antinociception. Vertical lines represent s.e.mean; between 14 and 16
mice were tested. *P50.05 in comparison with clonidine-treated
mice. (b) Enhancement by pinacidil (25 mg per mouse, i.c.v.) of
guanabenz (0.05 – 0.30 mg kg71, s.c.) antinociception. Vertical lines
represent s.e.mean; between 15 and 18 mice were tested. *P50.05 in
comparison with guanabenz-treated mice.
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The administration of the KATP channel blocker gliquidone
(6 mg per mouse, i.c.v.) prevented the antinociception induced
by clonidine (0.125 mg kg71, s.c.) and guanabenz
(0.30 mg kg71, s.c.) (Figure 4). A lower dose of gliquidone
(3 mg per mouse, i.c.v.) was ineective (Figure 4).
In the same experimental conditions, neither diazoxide,
minoxidil, pinacidil (Figure 2) nor gliquidone (Figure 4)
modified the licking latency values of mice when given alone.
Eect of an aODN to mKv1.1 on clonidine and
guanabenz antinociception
The eect produced by the antisense oligonucleotide (aODN)
to the mKv1.1 gene on clonidine (0.05 – 0.20 mg kg71, s.c.)
and guanabenz (0.05 – 0.50 mg kg71, s.c.) analgesia was
evaluated by using the mouse hot-plate test.
Repeated administration of aODN (2 nmol per i.c.v.
injection) prevented the antinociception induced by increasing
concentrations of clonidine (0.08 – 0.20 mg kg71, s.c.; Figure
5a) and guanabenz (0.10 – 0.50 mg kg71, s.c.; Figure 5b) in
comparison with the mice pretreated with the degenerate
oligonucleotide (dODN). The aODN prevented the enhance-
ment induced by the two a2-adrenoceptor agonists displacing
to the right the clonidine (Figure 5a) and guanabenz (Figure
5b) dose-response line in a parallel fashion. This antagonistic
eect was detected 72 h after the end of the aODN
administration. The pretreatment with the dODN never
modified clonidine and guanabenz antinociception in compar-
ison with vector i.c.v.-injected mice (data not shown).
The prevention of clonidine (0.125 mg kg71, s.c.) and
guanabenz (0.3 mg kg71, s.c.) analgesia produced by aODN
(2.0 nmol per i.c.v. injection) disappeared 7 days after the end
of the aODN pretreatment (clonidine: 27.3+1.8; cloni-
dine+aODN: 27.8+1.6; guanabenz: 28.5+1.3; guanabenz
+aODN: 28.3+0.9).
The aODN pretreatment did not reduce the pain threshold
in mice, having no hyperalgesic eect at both 72 h and 7 days
after the last i.c.v. injection (data not shown).
Eect of the Ca2+-activated K+ channel blocker apamin
on clonidine and guanabenz antinociception
The administration of apamin (0.5 – 2.0 ng per mouse, i.c.v.),
at all doses used, never modified the enhancement of the pain
threshold induced by clonidine (0.125 mg kg71, s.c.) as
illustrated in Figure 6. Furthermore, apamin, at the dose of
1.0 ng per mouse i.c.v., was not able to produce any eect on
guanabenz (0.3 mg kg71, s.c.) antinociception (Figure 6).
Apamin, when given alone, showed neither hyperalgesic nor
analgesic eect (Figure 6).
Higher doses of apamin were not investigated since, at
3.0 ng per mouse i.c.v., this compound produced convulsions
in mice.
Eect of clonidine and guanabenz on mouse rota-rod test
It should be noted that both clonidine and guanabenz, at the
doses used in the present work, elicited their antinociceptive
eect without changing either gross animal behaviour or
motor coordination as revealed by the rota-rod test. The rota-
Figure 4 Prevention by the KATP blocker gliquidone (3.0 – 6.0 mg
per mouse, i.c.v.) of clonidine (0.125 mg kg71, s.c.) and guanabenz
(0.30 mg kg71, s.c.) antinociception in the mouse hot-plate test. Each
column shows the dose of gliquidone administered. Vertical lines
represent s.e.mean; between 10 and 15 mice were tested. **P50.01 in
comparison with the corresponding analgesic-treated mice.
Figure 5 Eect of pretreatment with an antisense oligonucleotide
(aODN) to mKv1.1 gene on clonidine- and guanabenz-induced
antinociception in the mouse hot-plate test. (a) Prevention by aODN
(2.0 nmol per single i.c.v. injection) of clonidine (0.05 – 0.20 mg kg71,
s.c.) antinociception. The test was performed 72 h after the last i.c.v.
injection of degenerate ODN (dODN; 2.0 nmol per single i.c.v.
injection) or aODN. Vertical lines represent s.e.mean; between 12 and
16 mice were tested. *P50.05 in comparison with dODN+clonidine
group. (b) Prevention by aODN (2.0 nmol per single i.c.v. injection)
of guanabenz (0.02 – 0.50 mg kg71, s.c.) antinociception. The test was
72 h after the last i.c.v. injection of degenerate ODN (dODN;
2.0 nmol per single i.c.v. injection) or aODN. Vertical lines represent
s.e.mean; between 13 and 19 mice were tested. *P50.05; **P50.01
in comparison with dODN+guanabenz group.
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rod performance, evaluated as number of falls in 30 s, of mice
treated with clonidine at the doses of 0.125 (4.0+0.6) and
0.20 mg kg71 s.c. (3.8+0.3), and guanabenz at the doses of
0.30 (1.7+0.8) and 0.50 mg kg71 s.c. (3.9+0.8) was not
impaired in comparison with saline-treated mice (2.9+0.6).
On the contrary, clonidine and guanabenz administered at
higher doses (0.50 and 1.0 mg kg71, s.c., respectively),
produced a significant impairment of the rota-rod performance
by increasing the number of falls from the rotating rod
(5.8+0.4 and 5.9+0.7 respectively) in comparison with saline-
treated mice and with pretest values (5.0+0.6 and 5.1+0.7
respectively).
The number of falls were recorded in correspondence, with
the maximum analgesic eect of clonidine and guanabenz
which occurred respectively 30 and 75 min after administra-
tion.
Discussion
The present results indicate that neuronal K+ channels play an
important role in the mechanism of analgesic action of the a2-
adrenoceptor agonists clonidine and guanabenz.
The administration of gliquidone, a potent blocker of ATP-
dependent K+ channels (KATP) (Amoroso et al., 1990),
prevented the antinociception induced by both a2-adreno-
ceptor agonists investigated. Pretreatment with minoxidil,
pinacidil and diazoxide, openers of neuronal KATP channels
(Longman & Hamilton, 1992), potentiated the enhancement of
the pain threshold produced by clonidine and guanabenz. This
potentiation may occur because minoxidil, pinacidil and
diazoxide facilitate the opening of KATP channels induced by
the a2-adrenoceptor agonists. The functionality of KATP
channels appears, therefore, fundamental in the antinocicep-
tion produced by a2-adrenoceptor agonists. These observations
are in agreement with previous studies on the activity of
clonidine in which an antagonism of clonidine K+ con-
ductance by Ce2+, Ba2+ and Rb+, blockers of several types of
K+ channels including KATP channels (Quayle et al., 1988;
Criddle & Moura, 1995) was reported (Cherubini & North,
1985; Williams & North, 1985; Williams et al., 1988).
According to these electrophysiological data, behavioural
studies showed that dierent sulphonylureas, blockers of KATP
channels, antagonized clonidine antinociception (Ocan˜a &
Bayens, 1993; Raa & Martinez, 1995) whereas cromakalim, a
KATP channel opener in neurones (Edwards & Weston, 1993),
enhanced clonidine-induced antinociception in the mouse tail
flick test (Ocan˜a et al., 1996).
The present study also provides evidence for the involve-
ment of voltage-gated K+ channel in central antinociception
induced by a2-adrenoceptor agonists. By using an antisense
ODN (aODN) to the mKv1.1 gene coding for the mouse
Shaker-like Kv1.1, the importance of the integrity and
functionality of the above-mentioned K+ channel has been
evidenced. mKv1.1 is a K+ channel of the Shaker-like
subfamily that, when expressed in Xenopus oocytes, gives rise
to a fast activating, slowly inactivating K+ current (Hopkins &
Tempel, 1992). The investigation into the involvement of
mKv1.1 in central analgesia was carried out on the basis of its
wide distribution in the mammalian brain, including areas
involved in the modulation of the pain threshold (Wang et al.,
1994). Repeated i.c.v. administration of aODN to mKv1.1
prevented clondine and guanabenz antinociception. The
possibility that the antagonism exerted by aODN could be
caused by sequence-independent eects on cerebral structures
was ruled out since results obtained from a quantitative RT –
PCR indicated a lowering of mKv1.1 mRNA brain levels
specifically in the anti-mKv1.1 aODN-treated mice (Galeotti et
al., 1997). The inhibition of clonidine- and guanabenz-induced
enhancement of the pain threshold disappeared 7 days after the
last i.c.v. injection of the aODN indicating a lack of damage or
toxicity associated with aODN treatment.
The intracellular mechanism of analgesic action of clonidine
and guanabenz involves the activation of a pertussis toxin
(PTX)-sensitive G-protein, since not only clonidine, in
agreement with previous data (Sanchez-Blasquez & Garzon,
1991), but also guanabenz analgesia is prevented by the i.c.v.
administration of PTX. PTX-sensitive G-proteins represent the
most widespread modulatory signaling pathway in neurones
(Holz et al., 1986) and are responsible for modulation of ionic
conductance through a direct interaction with the ion channel
and/or by lowering intracellular cyclic AMP levels (Hille,
1994). The KATP channels can be opened through a mechanism
mediated by G-proteins. It has been reported that the
interaction between the a-GTP subunit and the KATP channel
produces a conformational change that stimulates the opening
of the channel (Edwards & Weston, 1993). In the presence of
GTPgS, a non hydrolysable GTP analogue, an irreversible
activation of KATP is obtained. Furthermore, the a subunits
involved in the modulation of KATP channel function have
been identified as belonging to the ai and ao subtypes (Edwards
& Weston, 1993). Also voltage-gated K+ channels can be
modulated by neurotransmitters and hormones in many
tissues. Indeed, protein kinase A modulation of delayed
rectifier-type K+ currents has been shown in the heart and in
lymphocytes (Giles et al., 1989; Soliven & Nelson, 1990). More
recently an increase in mKv1.1 K+ channel expression at the
levels of RNA, protein and current density in Chinese hamster
ovary cells was found as a result of reduced basal protein
kinase A activity (Bosma et al., 1993). PTX-sensitive G-
proteins can, therefore, modulate not only KATP but also
mKv1.1 channel function through a dierent mechanism: a
direct interaction (KATP) or a modulation of protein kinase A
levels (mKv1.1). From this evidence it is plausible to suppose
Figure 6 Lack of eect by the Ca2+-gated and K+ channel blocker
apamin (0.5 – 2.0 ng per mouse, i.c.v.) on clonidine (0.125 mg kg71,
s.c.) and guanabenz (0.30 mg kg71, s.c.) antinociception in the mouse
hot-plate test. Each column shows the dose of apamin administered.
Vertical lines give s.e.mean; there were 15 mice per group. *P50.01
in comparison with saline-treated mice.
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that both K+ channel subtypes are involved in a2-adrenoceptor
agonist-induced analgesia as an intracellular eector under-
lying the activation of a Gi/o protein.
The i.c.v. administration of the bee venom apamin, a
blocker of small (low) conductance Ca2+-gated K+ channels
(Rudy, 1988), did not modify the antinociception induced by
both clonidine and guanabenz, indicating the lack of
involvement of Ca2+-gated K+ channels in the modulation
of the pain threshold produced by activation of a2-
adrenoceptors. These results are in agreement with electro-
physiological studies in which apamin was unable to block the
inhibitory eect produced by clonidine on peripheral sensory
nerves (Stretton et al., 1992; Miura et al., 1992). Doses of
apamin higher than 2.0 ng per mouse i.c.v. were not
investigated since they induced convulsions in mice. However,
we can exclude that the lack of prevention exerted by apamin
could be due to the employment of inadequate concentrations
since, in the same range of doses used in the present study,
apamin was able to modulate dierent neuronal functions such
as learning and memory (Ghelardini et al., 1998) and food
consumption (Ghelardini et al., 1997).
In these experimental conditions, neither the K+ channel
blocker gliquidone and the aODN to mKv1.1, nor the K+
channel openers used modified the licking latency values of
mice in comparison with control groups. The lack of eect of
both gliquidone and aODN to mKv1.1 agrees with results of
studies in which these compounds did not modify the
nociceptive threshold against thermal noxious stimuli (Welch
& Dunlow, 1993; Raa & Martinez, 1995; Galeotti et al.,
1997). The administration of the K+ channel openers
diazoxide and minoxidil has been reported to induce
antinociception in the tail flick test, but this eect was
detectable only at doses higher than those employed in the
present study (Welch & Dunlow, 1993). We can, therefore,
exclude that the prevention or the enhancement of clonidine
and guanabenz antinociception is due respectively to a
hyperalgesic or analgesic eect of the K+ channel modulators
used.
Agonists of a2-adrenoceptors induce not only analgesia but
also numerous other pharmacological eects such as sedation
and hypotension (McDonald et al., 1997) whose appearance
could lead to an alteration of the licking latency values
observed in the hot-plate test. It has been, therefore, necessary
to choose a range of doses of clonidine and guanabenz at
which these compounds showed antinociceptive properties
without any behavioural side eects. Doses of clonidine and
guanabenz higher than 0.2 and 0.5 mg kg71, s.c. respectively
were not used because they impaired the mice’s rota-rod
performance. Similarly, the K+ channel modulators and the
aODN to mKv1.1 were used at doses which did not modify the
animals’ behaviour as revealed by the rota-rod and hole board
tests (Galeotti et al., 1997; Ghelardini et al., 1997; 1998).
In conclusion, the present data demonstrates that both
KATP and mKv1.1 K
+ channels are an important step in the
transduction mechanism underlying central antinociception
induced by activation of a2-adrenoceptors.
The authors wish to thank Mary Forrest for linguistic revision of
the manuscript. This work was supported by grants from MURST.
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